A Kent and Medway Cancer Network (KMCN) audit of second-line treatment for non-small cell lung cancer

被引：0
|
作者：
Cafferkey, C. [1 ]
Jamal-Hanjani, M. [1 ]
Beesley, S. [1 ]
Cominos, M. [1 ]
Sevitt, T. [1 ]
Taylor, H. [1 ]
Burcombe, R. [1 ]
Shah, R. [1 ]
机构：
[1] Maidstone Hlth Author, Maidstone, Kent, England
来源：
LUNG CANCER | 2010年 / 67卷
关键词：
D O I：
10.1016/S0169-5002(10)70022-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
21
引用
收藏
页码：S7 / S8
页数：2
相关论文
共 50 条
  • [41] Second-line treatment of small-cell lung cancer
    MacCallum C.
    Gillenwater H.H.
    Current Oncology Reports, 2006, 8 (4) : 258 - 264
  • [42] Experience with osimertinib in second-line treatment of non-small cell lung cancer at Nottingham University Hospitals
    Sadiq, M.
    Khan, S.
    Lopez-Escola, C.
    Arora, A.
    Hennig, I.
    Abdallah, S.
    Soomro, I.
    LUNG CANCER, 2020, 139 : S62 - S62
  • [43] Histologic review of second-line permetrexed treatment in patients with non-small cell lung cancer (NSCLC)
    Virani, S.
    Almubarak, M.
    Rogers, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer
    Holmes, J
    Dunlop, D
    Hemmett, L
    Sharplin, P
    Bose, U
    PHARMACOECONOMICS, 2004, 22 (09) : 581 - 589
  • [45] A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer
    Jeremy Holmes
    David Dunlop
    Lindsay Hemmett
    Peter Sharplin
    Uday Bose
    PharmacoEconomics, 2004, 22 : 581 - 589
  • [46] Pemetrexed vs docetaxel cost analysis in second-line non-small cell lung cancer treatment
    Ravasio, Roberto
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2005, 6 (02) : 119 - 126
  • [47] Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer
    Georgoulias, VA
    LUNG CANCER, 2002, 38 : S61 - S66
  • [48] First- and second-line biomarker utilization in non-small cell lung cancer
    Leong, Matthew
    Azimpouran, Mahzad
    McCloskey, Audrey
    Sankar, Kamya
    Vail, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer
    Laack, E
    Dierlamm, T
    Knuffmann, C
    Popp, J
    Schmied, B
    Dürk, H
    Wacker-Backerhaus, G
    Zeller, W
    Verpoort, K
    Fiedler, W
    Hossfeld, DK
    LUNG CANCER, 2002, 36 (03) : 303 - 307
  • [50] Use of novel second-line targeted therapies in non-small cell lung cancer
    Massarelli, E
    Herbst, RS
    SEMINARS IN ONCOLOGY, 2006, 33 (01) : S9 - S16
12345